Literature DB >> 33777292

Diagnosis of latent tuberculosis among HIV infected patients in Ilorin, Nigeria using tuberculin skin test and interferon gamma release assay.

Adeniyi Olatunji Aladesanmi1, Olutobi Babatope Ojuawo1, Olutosin Olukemi Aladesanmi2, Ademola Emmanuel Fawibe1, Olufemi Olumuyiwa Desalu1, Ayotade Boluwatife Ojuawo3, Christopher Muyiwa Opeyemi1, Mosunmoluwa Obafemi Adio1, Victoria Oluwaloniola4, Alakija Kazeem Salami1.   

Abstract

INTRODUCTION: Latent Tuberculosis Infection (LTBI) screening is recommended for individuals with a known risk factor for progression to active disease especially in the setting of HIV infection. This will ensure early diagnosis and prompt treatment. The purpose of our study was to compare tuberculin skin test (TST) with Interferon Gamma Release Assay (IGRA) in the diagnosis of LTBI among patients with known HIV infection at University of Ilorin Teaching Hospital (UITH), Ilorin.
METHODS: this was a hospital based cross-sectional study at the Highly Active Antiretroviral therapy (HAART) Clinic and medical wards of the University of Ilorin Teaching Hospital, Ilorin, Nigeria. A total of 282 consenting patients with HIV infection were recruited. Sociodemographic and clinical information was obtained using a well-structured questionnaire. The screening for LTBI was done using Tuberculin skin test (TST) and Interferon Gamma release assay (IGRA).
RESULTS: the prevalence of LTBI among HIV infected patients was 40.6% and 53.1% using TST and QFT-IT respectively, while the overall prevalence considering positivity to either of the test was 66%. There was mild agreement (κ: 0.218) between TST and QFT-IT in the diagnosis of LTBI among patients with HIV infection. The association between CD4 count and TST was not statistically significant (p value = 0.388) but there was strong association between CD4 cell count and QFT results (p = 0.001).
CONCLUSION: the prevalence of LTBI is quite high among patients with HIV infection in our locality. There is a need to encourage screening of at-risk individuals to forestall the morbidity and mortality associated with TB in this population. Copyright: Adeniyi Olatunji Aladesanmi et al.

Entities:  

Keywords:  HIV; Ilorin; Latent tuberculosis

Mesh:

Year:  2021        PMID: 33777292      PMCID: PMC7955607          DOI: 10.11604/pamj.2021.38.24.24039

Source DB:  PubMed          Journal:  Pan Afr Med J


  19 in total

1.  Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions.

Authors:  Haileyesus Getahun; Reuben Granich; Delphine Sculier; Christian Gunneberg; Leopold Blanc; Paul Nunn; Mario Raviglione
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

2.  The Global Plan to Stop TB, 2006-2015. actions for life: towards a world free of tuberculosis.

Authors: 
Journal:  Int J Tuberc Lung Dis       Date:  2006-03       Impact factor: 2.373

Review 3.  Controlled chemoprophylaxis trials in tuberculosis. A general review.

Authors:  S H Ferebee
Journal:  Bibl Tuberc       Date:  1970

Review 4.  The negative tuberculin test. Tuberculin, HIV, and anergy panels.

Authors:  E L Pesanti
Journal:  Am J Respir Crit Care Med       Date:  1994-06       Impact factor: 21.405

5.  Prevalence of latent TB infection in HIV infected persons in the Sylvanus Olympio teaching hospital of Lomé.

Authors:  K Adjoh; I M Wateba; O Tidjani
Journal:  Int J Mycobacteriol       Date:  2013-01-08

Review 6.  [A SYSTEMATIC REVIEW ON THE PREVALENCE AND INCIDENCE OF LATENT TUBERCULOSIS INFECTION AMONG PRISON POPULATION].

Authors:  Lisa Kawatsu; Kazuhiro Uchimura; Kiyohiko Izumi; Akihiro Ohkado
Journal:  Kekkaku       Date:  2016-04

7.  Update on the treatment of tuberculosis and latent tuberculosis infection.

Authors:  Henry M Blumberg; Michael K Leonard; Robert M Jasmer
Journal:  JAMA       Date:  2005-06-08       Impact factor: 56.272

8.  QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases.

Authors:  F Bartalesi; S Vicidomini; D Goletti; C Fiorelli; G Fiori; D Melchiorre; E Tortoli; A Mantella; M Benucci; E Girardi; M M Cerinic; A Bartoloni
Journal:  Eur Respir J       Date:  2008-12-01       Impact factor: 16.671

9.  Priorities for the treatment of latent tuberculosis infection in the United States.

Authors:  C Robert Horsburgh
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

10.  Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil.

Authors:  Gislene Maria Botão Kussen; Libera Maria Dalla-Costa; Andrea Rossoni; Sonia Mara Raboni
Journal:  Braz J Infect Dis       Date:  2015-12-17       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.